Metabolic Syndrome and Associated Factors Among People Living With HIV on Dolutegravir-Based Antiretroviral Therapy in Northern Tanzania

Overview

Journal J Int Assoc Provid AIDS Care

Publisher Sage Publications

Specialty Infectious Diseases

Date 2024 Dec 23

PMID 39714472

Authors

Tumaini E Mirai

Kajiru G Kilonzo

Abid M Sadiq

Ibrahim Ali Ibrahim Muhina

Norman J Kyala

Annette A Marandu

Sarah K Gharib

Andrea R Costantine

Elifuraha W Mkwizu

William P Howlett

Elichilia R Shao

Gissela B Nyakunga

Huda F Akrabi

Vibhu R Kshettry

Venance P Maro

Nyasatu G Chamba

Furaha S Lyamuya

Affiliations

Soon will be listed here.

Abstract

Purpose: Chronic systemic inflammation from human immunodeficiency virus (HIV) may cause metabolic abnormalities in lipid metabolism. Additionally, the development of metabolic syndrome has been associated with specific anti-retroviral therapy, particularly dolutegravir. This study aimed to determine the prevalence and associated factors of metabolic syndrome among people living with HIV on dolutegravir-based anti-retroviral therapy.

Methods: This was an analytical cross-sectional study conducted between October 1, 2022, and March 31, 2023, among 312 people living with HIV. A structured questionnaire was used to collect socio-demographic and clinical characteristics including anthropometric indices and a blood pressure reading. A blood sample was collected to measure plasma glucose levels and serum lipid levels. The outcome being metabolic syndrome, odds ratios were evaluated using logistic regression analysis, and a -value of <.05 was considered statistically significant.

Results: The prevalence of metabolic syndrome was 42.3%. Waist circumference (73%) and reduced high-density lipoprotein cholesterol (59.9%) were the most prevalent components. Factors associated with metabolic syndrome were patients aged 18-44 years (aOR: 3.10; 95% CI: 1.24-7.79; = .016), female gender (aOR: 5.40; 95% CI: 2.07-14.13; = .001), no physical activity (aOR: 4.00; 95% CI: 1.05-15.10; = .042), and patients who earned >300 000 Tanzanian shillings per month (aOR: 2.15; 95% CI: 1.07-4.32; = .032).

Conclusion: The prevalence of metabolic syndrome among patients on dolutegravir-based therapy is high. There is a need to adhere to routine screening of metabolic syndrome among people living with HIV on dolutegravir-based anti-retroviral therapy.

References

Bosho D, Dube L, Mega T, Adare D, Tesfaye M, Eshetie T . Prevalence and predictors of metabolic syndrome among people living with human immunodeficiency virus (PLWHIV). Diabetol Metab Syndr. 2018; 10:10. PMC: 5822556. DOI: 10.1186/s13098-018-0312-y. View

Ojong E, Iya B, Djeufouata J, Ndeh F, Nsonwu A, Njongang V . Metabolic syndrome and its components among HIV/AIDS patients on Antiretroviral Therapy and ART-Naïve Patients at the University of Calabar Teaching Hospital, Calabar, Nigeria. Afr Health Sci. 2022; 22(1):410-417. PMC: 9382514. DOI: 10.4314/ahs.v22i1.50. View

Asgedom Y, Kebede T, Gebrekidan A, Koyira M, Azeze G, Lombebo A . Prevalence of metabolic syndrome among people living with human immunodeficiency virus in sub-Saharan Africa: a systematic review and meta-analysis. Sci Rep. 2024; 14(1):11709. PMC: 11111734. DOI: 10.1038/s41598-024-62497-y. View

Fahed G, Aoun L, Zerdan M, Allam S, Zerdan M, Bouferraa Y . Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. Int J Mol Sci. 2022; 23(2). PMC: 8775991. DOI: 10.3390/ijms23020786. View

Todowede O, Mianda S, Sartorius B . Prevalence of metabolic syndrome among HIV-positive and HIV-negative populations in sub-Saharan Africa-a systematic review and meta-analysis. Syst Rev. 2019; 8(1):4. PMC: 6317235. DOI: 10.1186/s13643-018-0927-y. View

Wood B, Huhn G . Excess Weight Gain With Integrase Inhibitors and Tenofovir Alafenamide: What Is the Mechanism and Does It Matter?. Open Forum Infect Dis. 2021; 8(12):ofab542. PMC: 8643706. DOI: 10.1093/ofid/ofab542. View

Alberti K, Eckel R, Grundy S, Zimmet P, Cleeman J, Donato K . Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation;.... Circulation. 2009; 120(16):1640-5. DOI: 10.1161/CIRCULATIONAHA.109.192644. View

Venter W, Sokhela S, Simmons B, Moorhouse M, Fairlie L, Mashabane N . Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised,.... Lancet HIV. 2020; 7(10):e666-e676. DOI: 10.1016/S2352-3018(20)30241-1. View

Lagathu C, Bereziat V, Gorwood J, Fellahi S, Bastard J, Vigouroux C . Metabolic complications affecting adipose tissue, lipid and glucose metabolism associated with HIV antiretroviral treatment. Expert Opin Drug Saf. 2019; 18(9):829-840. DOI: 10.1080/14740338.2019.1644317. View

10.

Nalugga E, Laker E, Nabaggala M, Ddungu A, Batte C, Piloya T . Prevalence of overweight and obesity and associated factors among people living with HIV attending a tertiary care clinic in Uganda. BMC Nutr. 2022; 8(1):107. PMC: 9513878. DOI: 10.1186/s40795-022-00604-w. View

11.

Trachunthong D, Tipayamongkholgul M, Chumseng S, Darasawang W, Bundhamcharoen K . Burden of metabolic syndrome in the global adult HIV-infected population: a systematic review and meta-analysis. BMC Public Health. 2024; 24(1):2657. PMC: 11438355. DOI: 10.1186/s12889-024-20118-3. View

12.

Lee J, Kim Y, Jeon J . Association between physical activity and the prevalence of metabolic syndrome: from the Korean National Health and Nutrition Examination Survey, 1999-2012. Springerplus. 2016; 5(1):1870. PMC: 5080278. DOI: 10.1186/s40064-016-3514-5. View

13.

Bune G, Yalew A, Kumie A . The extents of metabolic syndrome among Antiretroviral Therapy exposed and ART naïve adult HIV patients in the Gedeo-zone, Southern-Ethiopia: a comparative cross-sectional study. Arch Public Health. 2020; 78:40. PMC: 7203886. DOI: 10.1186/s13690-020-00420-3. View

14.

Levi J, Wang J, Venter F, Hill A . Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment. Obesity (Silver Spring). 2023; 31(5):1270-1279. DOI: 10.1002/oby.23725. View

15.

Tovar Sanchez T, Mpoudi-Etame M, Kouanfack C, Delaporte E, Calmy A, Venter F . Risks of metabolic syndrome in the ADVANCE and NAMSAL trials. Front Reprod Health. 2023; 5:1133556. PMC: 10544962. DOI: 10.3389/frph.2023.1133556. View

16.

Haidar L, Crane H, Nance R, Webel A, Ruderman S, Whitney B . Weight loss associated with semaglutide treatment among people with HIV. AIDS. 2023; 38(4):531-535. PMC: 10922142. DOI: 10.1097/QAD.0000000000003791. View

17.

Esber A, Chang D, Iroezindu M, Bahemana E, Kibuuka H, Owuoth J . Weight gain during the dolutegravir transition in the African Cohort Study. J Int AIDS Soc. 2022; 25(4):e25899. PMC: 9008168. DOI: 10.1002/jia2.25899. View

18.

Steffen H, Mahanani M, Neuhann F, Nhlema A, Kasper P, de Forest A . Blood pressure changes during tenofovir-based antiretroviral therapy among people living with HIV in Lilongwe, Malawi: results from the prospective LighTen Cohort Study. Clin Res Cardiol. 2023; 112(11):1650-1663. PMC: 10584708. DOI: 10.1007/s00392-023-02253-w. View

19.

Byonanebye D, Polizzotto M, Maltez F, Rauch A, Grabmeier-Pfistershammer K, Wit F . Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre,.... Lancet HIV. 2024; 11(5):e321-e332. PMC: 11338627. DOI: 10.1016/S2352-3018(23)00328-4. View

20.

Lamorde M, Atwiine M, Owarwo N, Ddungu A, Laker E, Mubiru F . Dolutegravir-associated hyperglycaemia in patients with HIV. Lancet HIV. 2020; 7(7):e461-e462. DOI: 10.1016/S2352-3018(20)30042-4. View